A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(58 sites) United States
University of Alabama -Birmingham, Birmingham, Alabama Mayo Clinic Arizona, Phoenix, Arizona David Geffen School of Medicine, Los Angeles, California Hoag Memorial Hospital Presbyterian, Newport Beach, California Mayo Clinic-Jacksonville, Jacksonville, Florida Advent Health Orlando, Orlando, Florida Moffitt Cancer Center, Tampa, Florida Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois Henry Ford Hospital, Detroit, Michigan Regents of the University of Minnesota, Minneapolis, Minnesota Mayo Clinic, Rochester, Minnesota Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire Astera Cancer Care, East Brunswick, New Jersey John Theurer Cancer Center At Hackensack Umc, Hackensack, New Jersey New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone, Mineola, New York NYU Langone Hospital - Long Island, Mineola, New York Memorial Sloan Kettering Cancer Center, New York, New York Columbia University Hervert Irving Comprehensive Cancer Center, New York, New York Montefiore Medical Center, New York, New York Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania Thomas Jefferson University Hospital - Central, Philadelphia, Pennsylvania Scri Oncology Partners, Nashville, Tennessee Next Virginia, Fairfax, Virginia Northwest Cancer Specialists, P.C.-Vancouver, Vancouver, Washington Medical College of Wisconsin, Milwaukee, Wisconsin France
Hopital Albert Calmette - Chu Lille, Lille Hôpital de la Timone, Marseille Institut Curie - Site de Paris, Paris Chu Rennes - Hopital Pontchaillou, Rennes CHU Nantes - Hôpital Guillaume et René Laënnec, Saint-Herblain Institut Gustave Roussy, Villejuif Japan
NHO Himeji Medical Center, Himeji-shi Kansai Medical University Hospital, Hirakata-shi National Cancer Center Hospital East, Kashiwa The Cancer Institute Hospital of Jfcr, Kōtoku Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital, Kumamoto Shizuoka Cancer Center, Nagaizumi-cho Niigata Cancer Center Hospital, Niigata Okayama University Hospital, Okayama Kindai University Hospital, Ōsaka-sayama Tokushima University Hospital, Tokushima Fujita Health University Hospital, Toyoake-shi Spain
Hospital Clinic de Barcelona, Barcelona Hospital Universitari Vall D'Hebron, Barcelona Ico Girona - Hospital Universitari de Girona Dr Josep Trueta, Girona ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat Hospital General Universitario Gregorio Marañon, Madrid Hospital Universitario Ramon Y Cajal, Madrid Hospital Universitario 12 de Octubre, Madrid Hospital Regional Universitario de Malaga, Málaga Hospital Universitario Virgen Macarena, Seville Hospital Universitario Virgen Del Rocio, Seville Hospital Alvaro Cunqueiro, Vigo Key details Phase
Early testing / Safety & dosing
Collaborators
Merck Sharp & Dohme LLC
Enrollment target
~123 participants
Primary completion
September 2026
Last updated February 2026